IBRN stock forecast, quote, news & analysis

The most notable companies in this group are Biogen (NASDAQ:BIIB), Sarepta Therapeutics (NASDAQ:SRPT), Intra-Cellular Therapies (NASDAQ:ITCI), Avadel Pharmaceuticals plc (NASDAQ:AVDL).

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.

The average market capitalization across the iShares Neuroscience and Healthcare ETF ETF is 3.35B. The market cap for tickers in the group ranges from 24.83M to 35.35B. ARGX holds the highest valuation in this group at 35.35B. The lowest valued company is ATHA at 24.83M.

The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 22%. For the same ETF, the average monthly price growth was 68%, and the average quarterly price growth was 218%. SAVA experienced the highest price growth at 23%, while ALEC experienced the biggest fall at -23%.

The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was -4%. For the same stocks of the ETF, the average monthly volume growth was 45% and the average quarterly volume growth was 91%